Cliff Asness's TVTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 305,412 shares of Travere Therapeutics, Inc. (TVTX) worth $9.07 M, representing 0.00% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in TVTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 229,361 shares. Largest reduction occurred in Q2 2025, reducing 171,217 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Travere Therapeutics (TVTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Travere Therapeutics (TVTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -47,305 | Reduce 13.41% | 305,412 | $29.71 |
| Q4 2025 | +39,340 | Add 12.55% | 352,717 | $38.21 |
| Q3 2025 | +85,284 | Add 37.39% | 313,377 | $23.90 |
| Q2 2025 | -171,217 | Reduce 42.88% | 228,093 | $14.80 |
| Q1 2025 | -24,714 | Reduce 5.83% | 399,310 | $17.92 |
| Q4 2024 | +229,361 | Add 117.82% | 424,024 | $17.42 |
| Q3 2024 | +120,594 | Add 162.81% | 194,663 | $13.99 |
| Q2 2024 | +26,485 | Add 55.66% | 74,069 | $8.22 |
| Q1 2024 | +30,401 | Add 176.92% | 47,584 | $7.71 |
| Q4 2023 | -31,068 | Reduce 64.39% | 17,183 | $8.99 |
| Q3 2023 | +48,251 | New Buy | 48,251 | $8.94 |
| Q2 2023 | -9,898 | Sold Out | 0 | $0.00 |
| Q1 2023 | -8,388 | Reduce 45.87% | 9,898 | $22.49 |
| Q4 2022 | -12,691 | Reduce 40.97% | 18,286 | $21.03 |
| Q3 2022 | +6,307 | Add 25.57% | 30,977 | $24.63 |
| Q2 2022 | -38,753 | Reduce 61.10% | 24,670 | $24.24 |
| Q1 2022 | -11,796 | Reduce 15.68% | 63,423 | $25.76 |
| Q4 2021 | +10,457 | Add 16.15% | 75,219 | $31.04 |
| Q3 2021 | -15,970 | Reduce 19.78% | 64,762 | $24.24 |
| Q2 2021 | +34,931 | Add 76.27% | 80,732 | $14.59 |
| Q1 2021 | +15,944 | Add 53.40% | 45,801 | $24.98 |
| Q4 2020 | +29,857 | New Buy | 29,857 | $27.26 |
Cliff Asness's Travere Therapeutics Investment FAQs
Cliff Asness first purchased Travere Therapeutics, Inc. (TVTX) in Q4 2020, acquiring 29,857 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Travere Therapeutics, Inc. (TVTX) for 22 quarters since Q4 2020.
Cliff Asness's largest addition to Travere Therapeutics, Inc. (TVTX) was in Q4 2024, adding 424,024 shares worth $7.39 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 305,412 shares of Travere Therapeutics, Inc. (TVTX), valued at approximately $9.07 M.
As of the Q1 2026 filing, Travere Therapeutics, Inc. (TVTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Travere Therapeutics, Inc. (TVTX) was 424,024 shares, as reported at the end of Q4 2024.